Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced it received the 2019 Bio-IT World Conference & Expo Best of Show Award for Genedata Imagence® in the “No BS AI” category. Genedata Imagence is the industry’s first commercial, instrument-independent solution for automated high-content screening (HCS) image analysis at an enterprise scale, which applies a deep-learning approach. Judged by a Bio-IT World panel of experts from academia and industry, Genedata Imagence was recognized for its innovation and ability to “measurably improve workflow or capacity, enabling better research.”
Imagence Drives Research Forward
According to Bio-IT World judges, “imaging is the perfect use case for AI and the one with the most powerful and immediate impact. This new product – Genedata Imagence – is one the judges are excited to watch closely as it empowers biologists to make full use of AI to drive research forward.”
The deep learning-based solution accelerates, by orders of magnitude, the time-consuming and complex process of analyzing phenotypic high-content images. Delivering reproducible, unbiased results proven to be equal to or better than results from more traditional analysis approaches, Genedata Imagence enables biologists to quickly and routinely set up and analyze HCS campaigns without image analysis expertise. Specifically, Genedata Imagence:
“Genedata Imagence is revolutionizing a key process in biopharmaceutical R&D,” said Dr. Othmar Pfannes, CEO of Genedata. “We are honored to have Bio-IT World recognize the impact of this solution for improving the efficiency of data-driven drug discovery and development. Our early-access biopharma partners are already seeing the predicted gains in efficiency and scale-up of high-content screens with Imagence. We are now rolling out Imagence to the industry to advance research in the age of artificial intelligence.”
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, Singapore, and the US.
The statements in this press release that relate to future plans, events, or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.